GWAS have identified over 108 loci that confer risk for schizophrenia, but risk mechanisms for 32 individual loci are largely unknown. Using developmental, genetic, and illness-based RNA 33 sequencing expression analysis, we characterized the human brain transcriptome around these 34 loci and found enrichment for developmentally regulated genes with novel examples of shifting 35 isoform usage across pre-and post-natal life. Within patients and controls, we implemented a 36 novel algorithm for RNA quality adjustment, and identified 237 genes significantly associated 37 with diagnosis that replicated in an independent case-control dataset. These genes implicated 38 synaptic processes and were strongly regulated in early development (p < 10 -20 
48

Introduction: 49
Schizophrenia (SCZD) is a prevalent neuropsychiatric disorder with a combination of 50 genetic and environmental risk factors. Research over the last several decades has suggested 51 that SZCD is a neurodevelopmental disorder arising through altered connectivity and plasticity 52 in relevant neural circuits. However, discovering the causative mechanisms of these putatively 53 developmental deficits has been very challenging 1 . The most consistent evidence of etiologic 54 mechanisms related to SCZD has come from a recent genome-wide association study (GWAS) 55 in which over a hundred independent single nucleotide polymorphisms (SNPs) were identified 56 having an allele frequency difference between patients with schizophrenia and unaffected 57 controls 2 . While these findings have identified regions in the genome harboring genetic risk 58 variants, almost all of the associated SNPs are non-coding, located in intronic or intergenic 59 sequence, and hypothesized to have some role in regulating expression 3 . However, the exact 60 gene(s) and transcript(s) potentially regulated by risk-associated genetic variation are uncertain, 61
as most of these genomic regions contain multiple genes. In principle, the effects of non-coding 62 genetic variation, by whatever mechanisms (e.g. promoter, enhancer, splicing, noncoding RNA, 63
epigenetics, etc), should be observed in the transcriptome. Therefore, to better understand how 64 these regions of genetic risk and their underlying genotypes may confer risk of schizophrenia 65 and to better characterize the molecular biology of the disease state, we sequenced the polyA+ 66 transcriptomes from the prefrontal cortex of 495 individuals with ages across the lifespan, 67
ranging from the second trimester of fetal life to 85 years of age (see Table S1 ), including 175 68 patients with schizophrenia (see Figure S1 ). 69
Here we identify novel expression associations with genetic risk and with illness state 70 and explore developmentally regulated features, including a subset of genes with previously 71 uncharacterized isoform shifts in expression patterns across the fetal-postnatal developmental 72 transition. We further identify many more expression quantitative loci (eQTLs) in schizophrenia 73 risk regions then previously observed by surveying the full spectrum of associated expression 74 features to generate potential molecular mechanisms underlying genetic risk. We also explore 75 differential gene expression associated with the state of illness in a comparison of the 76 postmortem brains of patients with schizophrenia with non-psychiatric controls. By 77 incorporating a novel, experiment-based algorithm to account for RNA quality differences which 78
have not been adequately controlled in earlier studies, we report a high degree of replication 79 across independent case-control gene expression datasets 4, 5 . By combining genetic risk at the 80 population-level with eQTLs and case-control differences, we identify putative human frontal 81 cortex mechanisms underlying risk for schizophrenia and replicable molecular features of the 82 illness state. 83
84
Results
85
We performed deep polyA+ RNA-sequencing of 495 individuals, ranging in age from the 86 second trimester of fetal life to 85 years old (see Table S1 ), including 175 patients withschizophrenia (see Figure S1 ). We quantified expression across multiple transcript features, 88 including: annotated 1) genes and 2) exons, 3) annotation-guided transcripts 4 as well as 89 alignment-based 4) exon-exon splice junctions 5 and 5) expressed regions (ERs) 6 . These last 90 two expression features were selected to reduce reliance on the potentially incomplete 91 annotation of the brain transcriptome 7 (Results S1). We find a large number of moderately 92 expressed and previously unannotated splice junctions that tag potential transcripts with 93 alternative exonic boundaries or exon skipping ( Figure S2 ), 95% of which are also found in 94 other large RNA-seq datasets, including a subset that were brain-specific (Table 1) . Similarly, 95
we find that only 56.1% of ERs were annotated to strictly exonic sequence -many ERs 96 annotated to strictly intronic (22.3%) or intergenic (8.5%) sequence, or were transcribed beyond 97 existing annotation (e.g. extended UTRs, extended exonic sequence). 98
99
Developmental regulation of transcription and shifting isoform usage 100
Characterizing expression changes in unaffected individuals, particularly across brain 101 development beginning with prenatal life, has previously offered disease-relevant insights into 102 particular genomic loci [8] [9] [10] [11] [12] . Specifically, we and others 7, 13, 14 have shown that genomic risk loci 103 associated with neurodevelopmental disorders including schizophrenia are enriched for 104 transcript features showing differential expression between fetal and postnatal brains. Here too, 105 among the 320 control samples, the strongest component of expression change corresponded 106 to large expression changes in the contrast of pre-natal and early postnatal life, in line with 107 previous data 7 ( Figure 1A ). We further defined a developmental regulation statistic for each 108 expressed feature using a generalized additive model (see Methods) and found widespread 109 developmental regulation of these expressed features (Results S2, Table S3 , Figure S3 ), 110 including of previously unannotated sequence (Table S4 ). Motivated in part by previous reports 111 of preferential fetal isoform use among schizophrenia candidate risk genes 10, 11 (e.g predominant 112 fetal versus predominant postnatal isoforms), we next formally identified the subset of genes 113
showing alternative isoform expression patterns across fetal and postnatal life using those 114 exons, junctions, transcripts, and ERs that meet the statistical criteria for developmental 115 regulation (, i.e. those genes with at least one developmentally changing feature, see Methods).
116
There were 9,161 Ensembl genes (28% of the set of developmentally regulated genes) with 117 both positive and negative expression features having genome-wide significant correlations to 118 age (each with p bonf <0.05, Figure 1B , Table S5 , Figure S4 ). In other words, these represent 119 alternate transcript isoforms of the same gene that show opposite patterns of expression across 120 the prenatal-postnatal transition. 121
We performed gene set analyses of those genes with shifting isoform usage compared 122 to the larger set of genes with at least one developmentally regulated feature but without shifting 123 isoform usage to identify more specific biological functions of this unique form of developmental 124 regulation (Table S6 ). The set of developmentally shifting isoforms was relatively enriched for 125 localization, catalytic activity, signaling-related processes, including synaptic transmission and 126 cell communication, and neuronal development, among many others. Interestingly, genes 127 identified with shifting isoforms across development based exclusively on junction counts were 128 enriched for both dopaminergic (FDR=5.11x10 -7 ) and glutamatergic (FDR=4.02x10 -4 ) synapse 129 KEGG pathways ( Figure 1C ), the two neurotransmitter systems most prominently implicated in 130 schizophrenia pathogenesis and treatment. 131
132
Schizophrenia risk is associated with shifting isoform usage across brain development 133
Based on the KEGG analysis, we hypothesized that the genes with developmentally 134 regulated isoform shifts may relate to risk for schizophrenia. Indeed, genes within the SZCD 135 GWAS risk loci were more likely to harbor these isoform shifts occurring in the fetal-postnatal 136 developmental transition compared with the rest of the expressed transcriptome ( Figure 2D ).
137
For example, genes with developmental isoform shifts identified by exon and junction counts 138 were 62% (p=4.1x10 -5 ) and 69% (p=5.6x10 ) more likely to lie within the PGC2 risk regions 139 (with permutation-based p = 0.048 and 0.02 respectively, see Methods) than developmentally 140 regulated genes without isoforms shifts (Table S7) . These results further underscore the role of 141 changes in the regulation of transcription and splicing in early brain development in 142 schizophrenia risk. 143
144
Expression associations with chronic schizophrenia illness 145
We next explored the expression landscape of the prefrontal cortex of the schizophrenia 146 illness state and its potential link with developmental regulation and genetic risk. We performed 147 differential expression modeling using 351 higher quality adult samples (196 controls, 155 148 cases), and found extensive bias by RNA degradation within both univariate analysis (where 149 12,686 genes were differentially expressed at FDR<5%) and even after adjusting for measured 150 levels of RNA quality typical of all prior studies ( Figure S5 ). We therefore implemented a 151 statistical framework based on an independent molecular degradation experiment (see 152
Methods, Results S3), called "quality surrogate variable analysis" (qSVA, see Methods) 15 . We 153 further utilized replication RNA-seq data from the CommonMind Consortium (CMC) dataset, 154 using a subset of age range-matched 159 schizophrenia patients and 172 controls. 155
Interestingly, adjusting for observed factors related to RNA quality that characterize all earlier 156 studies of gene expression in schizophrenic brain, the proportion of genes with differentially 157 expressed features at genome wide significant FDR < 5% that replicate (with directionality and 158 marginal significance) in the CMC dataset was very small (only 11.0%, 244/2,215, Figure S6 ). In 159 contrast, using our new statistical qSVA approach, 40.1% of differentially expressed genes at 160 FDR < 5% (N=75/183) replicate in the CMC dataset. At genome-wide significant FDR<10% 161 (see Methods), we identified 237 genes with 556 DE features that replicated in the CMC dataset 162 (33.6% gene-level replication rate, Table S8, Table S9 ). 163
The differences in expression levels between cases and controls of these DE features 164
were generally small in both our discovery and the replication datasets ( Figure 2A , Figure S7 ), 165 perhaps a direct result of the clinical and molecular heterogeneity of this disorder 13, 16 . Gene 166 ontology analysis implicated transporter-and channel-related signaling as significantly 167 consistently downregulated in patients compared to controls across genes annotated in all three 168 expression summarizations ( Figure 2B , Table S10 ). These results suggested decreased 169 signaling in patients with schizophrenia, but could raise the possibility that these replicated 170 expression differences between patients and controls relate to the epiphenomena of illness, 171 such as treatment with antipsychotics which affect signaling in the brain 14 , as the majority of 172 patients were on anti-psychotics at the time of death (64% , Table S1 ). Only two genes (KLC1 173 and PPP2R3A) in the 108 significant schizophrenia GWAS loci were significantly differentially 174 expressed. However, in an exploratory analysis, we found that overall the differential expression 175 statistics within the loci were significantly different than those features outside the loci (Results 176 S4, Figure S8 , Table S11 ). We also investigated the relationships between transcription and 177 genomic risk for schizophrenia using genome wide Risk Profile Scores (RPS) from each subject 178 calculated as previously described 2 (see Methods). Using the subset of 209 Caucasian 179 samples, we largely found a lack of association between RPS and expression of individual 180 expression features. We further found a lack of enrichment of RPS on expression comparing the 181 differentially expressed and replicated case-control features to the rest of the transcriptome, as 182 well as lack of directionally consistency between RPS-and diagnosis-associated statistics 183 among expressed features (Table S12) .These results further suggest that the significant case-184 control expression differences show little overlap with genetic risk for the disorder. 185
In an earlier study of the epigenetic landscape of frontal cortex of patients with 186 schizophrenia, we showed that DNA methylation levels in patients were closer to fetal 187 methylation levels than to those of adult control samples
17
. Here we tested for analogous effects 188 in the RNA-seq data related to the illness state. Every significant gene with differentially 189 expressed features in the adult case-control analysis and replicated in the independent dataset 190 showed evidence for developmental regulation across at least two expression feature types. We 191 further found that the expression features normally more highly expressed in postnatal life 192 tended to be more lowly expressed in patients compared to controls (max: p=3.24x10 -11 , min:
, Figure 2C ) and features more highly expressed in fetal life tended to be more 194 highly expressed in patients with schizophrenia compared to controls regardless of 195 summarization type (max: p=6.86x10 -33 , min: p < 10 -100
, Figure 2D ). Analogous analyses for 196 developmental regulation of schizophrenia-associated features without adjusting for the RNA 197 quality qSVs were significant in the opposite directions, namely that schizophrenia-associated 198 changes were further from, rather than closer to, fetal expression levels, which would be 199 predicted as an artifact of residual RNA quality confounding (as the quality of the samples rank 200 as fetal > adult control > adult SZ, see Table S1 ).These results further converge on a role for 201 genes changing during brain development and maturation in schizophrenia, specifically that 202 both DNA methylation and expression levels in adult patients appear to reflect levels in the 203 developing brain more strongly than do those of unaffected individuals. These results also 204 underscore the risk of spurious findings based on uncorrected RNA quality confounding. 205
206
Clinical enrichment of eQTL associations for schizophrenia
In order to elucidate the RNA features associated with schizophrenia risk variants 208 themselves, rather than LD regions, we first performed a genome-wide cis (<500kb) expression 209 quantitative trait loci (eQTL) analysis within the 412 post-adolescent subjects (see Methods).
210
We then replicated SNP-feature eQTL pairs in two independent datasets (CMC and GTEx) to 211 form a significant and replicated set of high-confidence eQTLs ("core eQTLs") to interrogate for 212 clinical risk. Overall, we confirm widespread genetic control of expression in human brain 213 ( Figure 3A , Table S13, Table S14 ) which can be accessed by the research community via a 214 user friendly browser at eqtl.brainseq.org. The majority of these core eQTLs were largely gene-215 specific, consistent across both interrogated races (Results S5, Figure 3B ), very proximal to the 216 TSS of genes ( Figure 3C ), and expression of the majority of genes was associated with more 217 than 1 LD-independent SNP. We further found the largest effect sizes on average for the 218 junction and ER eQTLs ( Figure 3D ), and interestingly a large proportion of these eQTLs 219 corresponded to unannotated transcriptional activity. While the majority of genes with features 220 as eQTLs have multiple possible Ensembl transcript isoforms, 67.0% of exon eQTLs and 31.1% 221 of junction eQTLs were specific to a single Ensembl transcript when multiple transcripts existed 222 for a given gene. Together these eQTL results, based on analyses across multiple feature 223 summarizations from RNA sequencing data, demonstrate more widespread genetic regulation 224 of expression than previously reported, including extensive transcript specificity and regulation 225 of unannotated sequence in the human brain. These observations offer novel insights into cis 226 mechanisms of common variation in brain. 227
We next explored the landscape of eQTLs associated with genetic risk using the set of 228 core eQTLs among the PGC2-significant risk SNPs. There were 46 (42.5%) risk SNPs 229 significantly associated with expression levels of 764 nearby features at FDR < 1% significance 230 (Table S15 , of the 108/128 PGC2 "index" SNPs that were present in our data). This proportion 231 of SNPs was highly significant (p=4.6x10 ), further highlighting developmental relevance for schizophrenia 242 genetic risk. 243
244
Identifying risk transcripts through clinical and molecular convergence 245
In principle, transcripts with convergence of directionality of association with both genetic 246 risk and with clinical illness are especially attractive as putative molecular mechanisms of illness 247 and as candidates for designing pathogenic models. We therefore used allele information andthe corresponding effect estimates in the GWAS (odds ratio) and eQTL analyses (change in 249 expression per allele copy) to test which of the expressed features that differentiated patients 250 and controls were directionally consistent with the allelic directionality of genetic risk. In other 251 words, if a given allele at a risk associated SNP is associated with increased expression of a 252 nearby feature via the eQTL analysis, we tested whether expression of the same feature was 253 more likely to be higher in patients compared to controls (Results S6, Figure 4A ). Indeed, we 254 found two-fold enrichment of this directional consistency between the GWAS, case-control, and 255 FDR-significant eQTLs (p=4.2x10 -6 ). In order to reduce the chances of off-target eQTLs being 256 driven by correlated expression features, we lastly retained SNP-feature associations that were 257 at least half as significant on the log 10 scale as the best eQTL for each GWAS index SNP (e.g. if 258
the best eQTL association for a risk SNP was p < 1x10 -10 , then eQTLs with p > 1x10 -5 were 259 excluded). 260
This approach resulted in core eQTL signal across 34 GWAS loci with convergence of 261 allele and illness state expression directionality (encompassing 59 genes across 231 features, 262 Table S16 ). These are transcript features and genes that show consistent directionality of 263 association of genetic risk alleles and of illness state, implicating these as particularly likely 264 pathogenic factors underlying the GWAS loci. In the majority of these loci (N=22, 64.7%) the 265 eQTLs represented a single Ensembl gene, nominating it as the most well supported "risk 266 gene", based on schizophrenia genetic risk coupled to expression features in the polyA+ 267 fraction of postmortem DLPFC ( Figure 4 and Figure S9 ). Of the remaining 12 GWAS loci that 268 did not associate with features in only a single gene, 6 (17.6%) were similarly associated with 269 the expression of two nearby genes, which may indicate different candidate genes whose 270 expression is driven by different chromosomal haplotypes ( Figure 1B ). P-values provided for 470
Wilcoxon rank sign test for those features developmentally regulated among case-control 471 differences to those not developmentally regulated. 472 Transfer Agreement. Clinical characterization, diagnoses, and macro-and microscopic 580 neuropathological examinations were performed on all samples using a standardized paradigm, 581
and subjects with evidence of macro-or microscopic neuropathology were excluded. Details of 582 tissue acquisition, handling, processing, dissection, clinical characterization, diagnoses, 583 neuropathological examinations, RNA extraction and quality control measures were described 584 previously in Lipska, et al.
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. The Brain and Tissue Bank cases were handled in a similar 585 fashion (http://medschool.umaryland.edu/BTBank/ProtocolMethods.html). Antipsychotic use 586 was measured using toxicology at time of death. 587 588
RNA extraction and sequencing 589
Post-mortem tissue homogenates of dorsolateral prefrontal cortex grey matter (DLPFC) 590 approximating BA46/9 in postnatal samples and the corresponding region of PFC in fetal 591 samples were obtained from all subjects. Total RNA was extracted from ~100 mg of tissue using 592 the RNeasy kit (Qiagen) according to the manufacturer's protocol. The poly-A containing RNA 593 molecules were purified from 1 µg DNAse treated total RNA and sequencing libraries were 594 constructed using the Illumina TruSeq© RNA Sample Preparation v2 kit. Sequencing 595 indices/barcodes were inserted into Illumina adapters allowing samples to be multiplexed in 596 across lanes in each flow cell. These products were then purified and enriched with PCR to 597 create the final cDNA library for high throughput sequencing using an Illumina HiSeq 2000 with 598 paired end 2x100bp reads. 599 600 RNA sequencing data processing 601 602
The Illumina Real Time Analysis (RTA) module performed image analysis, base calling, and the 603 BCL Converter (CASAVA v1.8.2), generating FASTQ files containing the sequencing reads. 604
These reads were aligned to the human genome (UCSC hg19 build) using the spliced-read 605 mapper TopHat (v2.0.4) using the reference transcriptome to initially guide alignment, based on 606 known transcripts of the previous Ensembl build GRCh37.67 (the "-G" argument in the 607 software) 24 . We achieved a median of 85.3 million (IQR: 71.7M-111.2M) aligned reads per 608
sample (see Table S1 ). 609 610
We characterized the transcriptomes of these 495 samples using five convergent 611 measurements of expression ("feature summarizations")-(1) gene and (2) exon counts, and (3) 612 transcript-level quantifications that rely on existing gene annotation, and two annotation-613 agnostic approaches we have developed that are determined solely from the read alignments -614 (4) read coverage supporting exon-exon splice junctions (e.g. coordinates of potentially intronic 615 sequence that are spliced out of mature transcripts captured by a single read) and (5) read 616 coverage overlapping each base in each sample which we have summarized into contiguous 617 "expressed regions" (ERs, see Methods, Figure S1 ). These last three measurements generate 618 expression for features of interest that can "tag" elements of transcripts in the data that are not 619 constrained by limitations or incompleteness of existing annotation, and the counts for these 620 features can then be directly used for differential expression analysis. 621
1. Gene counts were generated using the featureCounts tool 25 based on the more recent 622 Ensembl v75, which was the last stable release for the hg19 genome build, using single end 623 read counting [featureCounts -a $GTF -o $OUT $BAM]. We converted counts to RPKM 624 values using the total number of aligned reads across the autosomal and sex chromosomes 625 (dropping reads mapping to the mitochondria chromosome). 626 2. Exon counts were also generated using the featureCounts tool 25 based on the more recent 627
Ensembl v75, using single end read counting, and allowing reads to be assigned to multiple 628 exons (e.g. those with splice junctions) [featureCounts -O -f -a $GTF -o $OUT $BAM]. We 629 converted counts to RPKM values using the total number of aligned reads across the 630 autosomal and sex chromosomes (dropping reads mapping to the mitochondria 631 chromosome). 632 3. Junction counts were generated by first filtering the TopHat BAM file to primary alignments 633 only [samtools view -bh -F 0x100 $BAM > $NEWBAM ] and regtools 26 was used to extract 634 analogous junction information (coordinates and number of reads supporting) as the TopHat 635 output. We found that native TopHat output (junctions.bed) was based on both primary and 636 secondary alignments, which could influence the degree of potentially novel splice junctions.
637
We used a modified version of TopHat's "bed_to_juncs" program to retain the number of 638 supporting reads (in addition to returning the coordinates of the spliced sequence, rather 639 than the maximum fragment range), and used R code (see Supplementary Code) to 640 combine and annotate these junctions across all samples. We annotated identified splice 641 junctions using Ensembl v75 -while the initial alignment was guided by Ensembl v67, novel 642 junctions, by definition, are identified in the second genome alignment, rather than the initial 643 guided transcriptome alignment step. We converted counts to "RP80M" values, or "reads per 644 80 million mapped" using the total number of aligned reads across the autosomal and sex 645 chromosomes (dropping reads mapping to the mitochondria chromosome), which can be 646 interpreted as the number of reads supporting the junction in an average library size (we 647 were targeting 80M reads in the sequencing , with the imputation reference set from the full 1000 Human Genomes Project Phase 672 3 data set, separately by platform. We retained common SNPs (MAF > 5%) that were present in 673 the majority of samples (missingness < 10%) that were in Hardy Weinberg equilibrium (at p > 674 1x10 -6 ) using the Plink 32 version 1.9 tool kit [`plink --bfile $BFILE --geno 0. all samples as the number of tests (which varied by feature type). We also computed post-hoc 739 statistics on the data, including the Pearson correlation between "cleaned" expression (after 740 regressing out the effects of sex and ethnicity, holding the age effects constant), and age to 741 determine if the expression of the fetal rose or fell across the lifespan, and also measured the 742 fetal versus postnatal log 2 fold changes. 743
Preferential isoform usage across aging was determined by identifying the subset of genes (by 744
Ensembl ID) that contained at least one Bonferroni-significant feature that had positive 745 correlation with age and another Bonferroni-significant feature that had negative correlation with 746 age. We also computed the difference in positive and negative correlations as a measure of the 747 magnitude of the preferential isoform use. Gene set analyses using pre-defined gene ontology 748 (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) sets were performed using the 749 clusterProfiler R/Bioconductor package 35 , here using the genes (mapping from Ensembl to 750 Entrez ID) that had such preferential isoform use to those that were developmentally regulated 751 (having at least one feature that was associate with age at Bonferroni significance).
752
Enrichments with the PGC2 schizophrenia risk loci -defined by the chr:start-end roughly 753 corresponding to linkage disequilibrium blocks in the published manuscript -were performed 754 both parametrically, by overlapping the genomic coordinates of the 108 risk regions with those 755 genes that had preferential isoform usage, compared to a background of all genes with each set 756 of expressed features, as well as by permuting the locations of the 108 regions across the 757 genome 10,000 times and each time, re-computing the overlap within these null regions -see 758 additional details in Jaffe et al 2015 7 . Empirical p-values were calculated by counting the 759 number of the odds ratios across the 10,000 null permutations to each observed odds ratio. In these replication data we did not perform FDR correction. We were using the study for 820 replication, not discovery, and therefore only used the features that were expressed in our data 821 regardless of the expression levels in CMC. We considered features independently replicated if 822 they had the same directionality for the SCZD versus control log 2 fold change and were 823 marginally significant (at p < 0.05) in the CMC dataset. 824
Gene set analyses on replicated differentially expressed features and genes were performed 825 with clusterProfiler 35 as described above. Table S9 . 866
We calculated the corresponding principal components (PCs) across all expression features 867 separately in the 547 samples, as in the discovery data, and in our tests for replication, modeled 868 the log2-transformed expression data as a function of additive genotype effect, controlling for 869 the top 10 expression PCs per summary type and the first 3 ancestry MDS components from 870 the genetic data. We lastly used the allele information to ensure additive effects across study 871 were relative to the same allele, flipping the directionality of such effects where the major allele 872 in one study corresponded to the minor allele in the other study. The eQTLs that were 873 directionality consistent (same allelic directionality of the additive effect on expression) and had 874 marginal significance (p<0.01) were considered replicated and retained for summarization. 875
GTEx: we performed analogous replication analyses as described above across the 1184 GTEx 876 brain samples that had genotype and RNA-seq data. While we calculated eQTL replication 877 statistics separately by brain region, we adjusted for the first 10 expression PCs from the entire 878 sample (across all brain regions), as well as MDS ancestry components from across the 879 genome. We only considered eQTLs from the frontal cortex brain region for replication, 880 enforcing directional consistency as the data set was much smaller than both our discovery and 881 first replication dataset (N=99). 882
After computing replication statistics in the CMC and GTEx frontal cortex datasets, the eQTLs 883 that were directionality consistent (same allelic directionality of the additive effect on expression) 884 in both datasets and had marginal significance (p<0.01) in CommonMind were considered 885 replicated and retained for summarization (see Table S9 ). Factors positively influencing 886 replication were, as expected, the statistical magnitude of the eQTL effect (absolute T
Clinical enrichment analyses: 891
We first calculated the "risk" effects of the schizophrenia GWAS variants using the set of all 892 GWAS results from: https://www.med.unc.edu/pgc/files/resultfiles/scz2.snp.results.txt.gz and 893
identified which allele at each SNP corresponded to increased risk, e.g. a positive odds ratio.
894
We then used these risk alleles to convert the directionality of our eQTL effects to reflect the 895 reference allele being the risk allele (rather than the minor allele Alan Cross, and Nicholas J.Brandon were full time employees and shareholders in AstraZeneca 960 at the time these studies were conducted. 961
The remaining authors declare no competing financial interests. Table S8 : eQTL replication metrics for CommonMind Consortium, GTEx frontal cortex, and both 1015 among all significant eQTLs in the discovery adult sample. 1016 Table S9 : eQTL statistics for the best SNP-feature pair in the discovery sample that replicated 1017 in CMC and GTEx frontal cortex, by feature type. 1018 Table S10 : Differential expression statistics for those features that were significant and 1019 replicated in case-control comparisons. 1020 Table S11 : Genes consistently differentially expressed by case-control analysis for the different 1021 feature summarizations. 1022 Table 2 with Ensembl transcript annotation data to highlight transcript 1038 specificity. 1039 
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Interestingly, analogous analyses for developmental regulation of schizophrenia-associated features without adjusting for the RNA quality qSVs were significant in the opposite directions, namely that schizophrenia-associated changes were further from, rather than closer to, fetal expression levels, which would be predicted as an effect of residual RNA quality confounding (as the quality of the samples were ranked fetal > adult control > adult SZ, see Table S1 ). This directional difference in RNA quality between fetal and postnatal samples is also typical of earlier studies (e.g. Colantuoni, Geschwind, etc).
GWAS implications of illness-associated expression differences
Only two genes in the 108 significant schizophrenia GWAS loci (KLC1 and PPP2R3A) had expression features significantly differentially expressed and replicated. To potentially identify more subtle associations within these GWAS risk regions, we performed an exploratory "feature set" analysis (analogous to traditional gene set analyses) comparing the schizophrenia differential expression statistics of all expressed features within the loci to those outside the loci. We found decreased expression of the 15,050 expressed features within the risk loci in patients compared to controls, relative to the 996,775 expressed features outside of the loci, adjusting for mean expression level ( Figure S8A , p =3.32x10 -36 , Table S13 ). While the absolute set-level effect sizes were small, these GWAS region-level associations were largely consistent when stratified by summarization type, with the exception of transcript counts which showed no association. Of particular importance is the observation that these findings also were only significant after quality adjustment in the differential expression analysis (Figures S8B-F) analyses adjusting for only the usual observed confounders (e.g. clinical covariates and observed quality variable) showed no enrichment among PGC risk regions (p=0.2, Table S13 ). Therefore, while many of the case-control expression differences that meet both genome-wide statistical significance and replication criteria may be related to schizophrenia treatment and epiphenomena and depleted for GWAS regions, some differences in expression in some subsets of patient populations might be related to genetic risk for the disorder, though the biological interpretation of the feature distribution differences is not clear. Larger studies can likely improve power to detect expression changes within the GWAS risk regions amidst the clinical and molecular heterogeneity of schizophrenia.
Genetic control of RNA expression levels in the cortex
In order to elucidate the RNA features associated with schizophrenia risk variants themselves, rather than LD regions, we first performed a cis (<500kb) genome-wide expression quantitative trait loci (eQTL) analysis across the five expression feature summarizations. These analyses were performed within the post-adolescent subjects, including both cases and controls (age > 13, N=412) across densely observed and imputed common and high-quality SNP genotypes (MAF > 5%, N=7,421,423), adjusting for components related to ancestry and expression heterogeneity in each feature type (see Methods). Given the large number of tests, but also the need for comparability across the five expression summarizations, we adjusted for multiple testing using both the false discovery rate (FDR) with a cutoff of 1%, in line with the GTEX project 2 and also a more stringent Bonferroni-based cutoff adjusting for the number of LD-independent SNP-feature pairs. These multiple testing thresholds corresponded to p<1.0x10 -4 and p<2.6x10 , respectively, across the 5 feature summarizations.
We examined only eQTL associations of 682,828 unique genetic variants to a total of 70,204 nearby expression features, mapping back to 9,271 Ensembl IDs (of which 7,057 had HGNC symbols) that were at Bonferroni significance in our dataset and that replicated in the two independent datasets ( Figure 3A , Table S10 ). We highlight the best SNP for each feature in Table S11 , and have a complete database, including statistics and visualizations, of all significant and replicated eQTLs online (as well as significant control-only eQTLs) via a user friendly browser at http://eqtl.brainseq.org.The majority of eQTLs (N=417,276, 61.1%) associated with features in a single Ensembl gene, and another large subset associated with features in two nearby genes (N=133,286, 19.5%). Conversely, the majority of genes were associated with more than 1 LD-independent SNP (76.3%) across the feature summarizations, including approximately half (49.0%) of genes having features associated with more than 3 LDindependent SNPs, suggesting that multiple variants can associate with expression independently of each other, and potentially result in more normally-distributed expression levels at the population-level. Furthermore, the eQTL effects (discovered in multiple/mixed ancestries) were largely consistent between Caucasian and African American subjects ( Figure  2B ). The most significant SNP for each eQTL feature was extremely proximal to the feature (based on nearest coordinate), with a median < 50bp (IQR less than -15kb to 15kb, Figure 2C ). Lastly, we found the largest effect sizes on average for the junction and ER eQTLs (see Supplementary Results, Figure 2D ).
While the majority of genes with features as eQTLs have multiple possible Ensembl isoforms, 67.0% of exon eQTLs and 31.1% of junction eQTLs were specific to a single Ensembl transcript when multiple transcripts existed for a given gene. Furthermore, 640 (11.2%), 1,123 (37.5%) and 10,698 (52.7%) of replicated junction, transcript, and expressed region eQTLs respectively, corresponded to novel transcriptional activity, including 387 alternative exonic boundary and 253 exon-skipping junction eQTLs and 4,036 alternative exonic boundary (crossing an intron and exon, and extended UTRs) and 6,662 intronic and intergenic ERs. These results indicate that performing both exon-and junction-level eQTL analyses together provide an encompassing view of genetic regulation of expression, as exon-level analyses identified eQTLs for the most genes as well as transcript-specific events, and junction-level analysis provided the largest biological effect sizes and the ability to identify potentially novel transcript isoforms. Together these eQTL results, based on analyses across multiple feature summarizations from RNA sequencing data, demonstrate more widespread genetic regulation of expression than previously reported, including extensive transcript specificity and regulation of unannotated sequence in the human brain.
There was moderate concordance across the different feature summarizations. Exonlevel summarizations resulted in the largest number of unique genes as eQTLs (N=6,698) and transcript-level summarizations resulted in the fewest (N=1,708). While the junction eQTLs were less likely to appear in the GTEX project likely because of the lower coverage, and therefore replicate, those that did replicate tended to have larger effect sizes than other summarizations, with a median 36% (IQR: 19-63%) change in expression per allele copy ( Figure 2D) . Expressed region-level analysis identified the second most eQTLs to unique genes (N=5,381) and effect sizes (median: 25%, IQR: 16-42%). Gene-level eQTL analysis, which is the de-facto approach in RNA-seq analysis, resulted in the smallest eQTL effects, with a 7% (IQR: 4-11%) change in expression per allele copy, and identified fewer unique genes than exon and expressed region analysis (N=4,934). These data suggest that most eQTLs involve specific transcript isoforms whose signals may be diluted when examining only gene-level expression data. If this dilution when using gene counts results from averaging over potentially transcript-specific eQTLs, then mapping all expressed features (sans expressed regions) to all known Ensembl transcripts, and tabulating the proportion of eQTLs that appear relatively transcript specific should confirm this.
In fact, there was extensive evidence of transcript-specificity of replicated eQTLs across exons, junctions, and transcripts.
Characterization of schizophrenia risk-associated expressed features
We found significant enrichment of this directional consistency between the GWAS, casecontrol, and FDR-significant (34 loci across 444 eQTL features and 91 Ensembl genes, OR=2.00, p=4.2x10 -6 ) as well as with the more conservative Bonferroni-significant (19 loci across 161 features and 44 Ensembl genes, OR=4.67, p=7.97x10 -8 ) features
The majority of our eQTLs (SNP-feature pairs) had directionally consistent allelic effects in the 50 fetal samples (N=628, 82.2%, p < 10 -20
) and a subset were marginally significant (at p < 0.05) even in this small sample size (N=162, 21.2%). As further evidence for similar genetic regulation, every eQTL that was marginally significant in the fetal samples was directionally consistent with the eQTL effect in the adult samples. For example, we find the most significant and replicated association with clinical directional consistency between rs4523957 (PGC rank 47) and exons (as well as other feature types, see Table S15 ) in Serine Racemase (SRR, Figure 4B ), an NMDAR modulator previously associated with schizophrenia 3 . While the statistical significance of exon associations were only slightly better than at the gene level (2.1x10 -12 versus 5.44x10 -11 ), the effect size was almost three times larger (-0.16 versus -0.06). Similarly we identified significant eQTL association between rs324017 (PGC rank 103), and exon-and junction-level expression of STAT6 ( Figure 4C ), a transcription factor involved in interleukin signaling 4 whereas there were no significant and replicated eQTLs at the gene-level.
The approach that was unconstrained by annotation also identified novel associations to schizophrenia risk, for example, the eQTL of rs6434928 (PGC rank 33) with intronic sequence in the HSPD1 and HSPE1 heat shock protein genes ( Figure 4D,E) , which are co-chaperonins linked by a common bidirectional promoter 5 . While both genes were recently highlighted in the subset of 20 PGC GWAS genes that are targets of currently approved drugs 6 , the strictly intronic annotation of the eQTL association may suggest a different mechanism of risk from this locus in schizophrenia, and thus a different requirement for a therapeutic agent. Finally, we highlight the eQTL association between rs13240464 (PGC rank 16) and the expression level of a novel splice junction in IMMP2L ( Figure 4F,G) , a gene important in directing mitochondrial proteins to the mitochondria 7 and that has been previously associated with autism and Tourette In the original GWAS report, while there were only 18 reported index SNPs with brain eQTLs to a total of 30 genes, many of the reported eQTLs were themselves not GWASsignificant variants, being only weakly linked (at R 2 < 0.6) to the best GWAS SNP. There were only three of these 18 GWAS-and eQTL-significant index SNPs (putatively associating with C10orf32 (BORCS7), AS3MT, OGFOD2, NAGA, and CENPM) that were present in our larger RNA-seq data from the three independent studies that we surveyed. Similarly, a recent GWAS and eQTL integration analysis based on peripheral blood eQTLs identified very few overlapping genes 10 . These genes included PCCB, SNX19, GATAD2A, and IRF3 as directionally-consistent eQTLs (with regard to the GWAS, eQTL, and case-control differences described above), and SF3B1 and PSMA4 as non-directionally consistent eQTLs, suggesting the need to query the disease-relevant tissue, i.e. human brain. Interrogating annotation-agnostic expression features added a considerable number of loci with eQTL signal further highlighting the value of RNA sequencing-based datasets. For example, we have recently dissected the GWAS signal in the 10q24.32 region in a more focused analysis based on the expression features highlighted in the current report. There we identified based on junction-level analysis a novel risk-associated isoform of AS3MT that is missing exons 2 and 3 11 . This analysis showed that the previously referenced genetic association with this locus to AS3MT was inaccurate, as no association was found to the full length AS3MT 11 , and importantly, the novel isoform does not have arsenic methyltransferase activity. Furthermore, eight additional loci, with clinical risk variants associating with expression of SNX19, NRGN/VSIG2, HSPD1, GATAD2A/NDUGA13, VPS45, GPM6A, SOX2-OT, and BRINP2, were identified here (and subsequently replicated) only via junction-and expressed region-level analysis.
